Standard disease-directed therapy

DRUG2 trials

Sponsors

Incyte Corporation

Conditions

Myeloproliferative Neoplasms

Phase 1

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Active, not recruitingNCT06313593

Incyte CorporationMyeloproliferative Neoplasms

Start: 2024-08-08End: 2028-10-09Updated: 2026-08-12

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

RecruitingNCT07441694

Incyte CorporationMyeloproliferative Neoplasms

Start: 2026-05-11End: 2030-05-24Target: 218Updated: 2026-07-22

Related Papers

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Blood2025-11-03

INCB160058 selectively targets JAK2V617F-driven hematopoiesis in diverse and drug-resistant models of myeloproliferative neoplasms

Blood2025-11-03